This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsActicor Biotech SAS（7V7）株式概要Acticor Biotech SAS社は、急性血栓性疾患の治療薬を開発する臨床段階のバイオ医薬品会社である。 詳細7V7 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析収益が 100 万ドル未満 ( €0 )マイナスの株主資本 過去5年間で収益は年間22.8%減少しました。 意味のある時価総額がありません ( €4M )+2 さらなるリスクすべてのリスクチェックを見る7V7 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.75該当なし内在価値ディスカウントEst. Revenue$PastFuture-19m25k2016201920222025202620282031Revenue €1.0Earnings €0.2AdvancedSet Fair ValueView all narrativesActicor Biotech SAS 競合他社co.donSymbol: XTRA:CNWMarket cap: €6.5mMedigeneSymbol: XTRA:MDG1Market cap: €1.8m4SCSymbol: DB:VSCMarket cap: €1.1mbioXXmedSymbol: XTRA:T5O0Market cap: €329.8k価格と性能株価の高値、安値、推移の概要Acticor Biotech SAS過去の株価現在の株価€0.7552週高値€4.0752週安値€0.22ベータ-0.291ヶ月の変化0%3ヶ月変化8.75%1年変化-74.28%3年間の変化-86.39%5年間の変化n/aIPOからの変化-88.83%最新ニュースお知らせ • Mar 07Acticor Biotech SAS(ENXTPA:ALACT) dropped from Next Biotech IndexActicor Biotech SAS has been dropped from the Next Biotech Index.お知らせ • Oct 14Acticor Biotech Announces Chief Financial Officer ChangesActicor Biotech announced the appointment of François Guillet as Chief Financial Officer, replacing Éric Cohen who is leaving to pursue other projects. With over 30 years' experience in financial management, François Guillet will bring to Acticor Biotech his expertise in financial structuring and optimization. His role will be to strengthen the management of the company's finances, while ensuring long-term visibility of Acticor Biotech's global strategy. François Guillet has held positions of great responsibility in companies in a wide variety of sectors, including the high-tech sector, from software publishing at Bea, Oracle and Adobe to the internet, electronics and e-commerce at Monnier Frères. He has contributed to restructuring and turnaround projects in mid-sized companies, with scope extended to Human Resources, Purchasing and Sales Administration. His previous assignments have included managing accounting closures, due diligence and managing multicultural teams internationally, reinforcing his versatility as a financial leader.お知らせ • Oct 11Acticor Biotech Repositions Glenzocimab in the Treatment of Myocardial InfarctionACTICOR BIOTECH provided an update on its clinical developments evaluating glenzocimab in the treatment of myocardial infarction. LIBERATE: A phase 2b study evaluating glenzocimab in the treatment of myocardial infarction. The LIBERATE phase 2b, randomized and double-blind study will include more than 212 patients suffering from ST-Elevation Myocardial Infarction (STEMI) who are scheduled to undergo percutaneous coronary intervention (PCI). The study’s primary objective is to assess the safety and efficacy of glenzocimab 1,000 mg compared to placebo, in reducing the size of the myocardial infarction 90 days post-event. This study is being conducted in partnership with the University of Birmingham (UK), with clinical experts from the Institute of Cardiovascular Sciences and University Hospitals Birmingham NHS Foundation Trust. The two leading clinical research sites, Queen Elizabeth Hospital in Birmingham and Northern General Hospitalin Sheffield, have been actively recruiting patients since January 2024. To date, 27 patients have been recruited, and study results are expected in Fourth Quarter of 2026. GLORIA: A phase 2 study evaluating glenzocimab in myocardial infarction treatment. A new phase 2 study GLORIA, randomized and double-blind, is being prepared to evaluate glenzocimab in the treatment of myocardial infarction. The study will enroll around 300 patients suffering from STEMI upon emergency admission to cardiac intensive care units. The study’s primary objective is likewise to assess the efficacy of glenzocimab for reducing the surface of myocardial infarct at Day 90 post PCI (Percutaneous Coronary Intervention), as well as safety. The study plans to test several dose levels and optimize the mode of administration to suit the time required for this emergency procedure. The aim of launching this second study, which could be promoted by the Company, is to provide all the clinical and regulatory elements required for a phase 3 registration as early as 2027, while evolving the product's mode of administration to facilitate the next stage of development and, later, adoption by clinicians. Patient recruitment could begin in First Quarter 2025, subject to the Company's financing or the continuation of the project as envisaged in the receivership procedure.Board Change • Sep 17Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Patricia Zilliox was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 14Acticor Biotech SAS, Annual General Meeting, Oct 25, 2024Acticor Biotech SAS, Annual General Meeting, Oct 25, 2024. Location: 82 avenue du maine, paris Franceお知らせ • Jul 26Acticor Biotech Announces the Conclusions of the Interim Futility Analysis in the Green StudyActicor Biotech announced the conclusions of the futility analysis of the phase 2/3 GREEN study evaluating glenzocimab as an adjunct to mechanical thrombectomy in acute ischemic stroke. In the light of the information provided to the members of the Independent Monitoring Committee (IMC), and in accordance with the futility criteria defined in the protocol, the IMC recommends that the GREEN study be discontinued. In light of the Committee's recommendations, sponsor Assistance Publique Hôpitaux de Paris (APHP), in agreement with Professor Mikaël Mazighi, principal investigator of the study, has decided to stop the GREEN study and halt enrolment. To date, 108 patients have been included in the study, the futility analysis only covered the first 78 patients, and all included patients will be analysed after the 90-day protocol follow-up. The GREEN study, sponsored by Assistance Publique - Hôpitaux de Paris, is part of the RHU BOOSTER program, with financial support from the Agence Nationale de la Recherche and the Programme Investissements d'Avenir. GREEN (Glenzocimab for REperfusion in the setting of Endovascular therapy for brain infarctioN) is a randomized, double-blind, multicenter, placebo-controlled Phase 2/3 study of the efficacy and safety of glenzocimab as an adjunct to mechanical thrombectomy in the first 24 hours of acute ischemic stroke.最新情報をもっと見るRecent updatesお知らせ • Mar 07Acticor Biotech SAS(ENXTPA:ALACT) dropped from Next Biotech IndexActicor Biotech SAS has been dropped from the Next Biotech Index.お知らせ • Oct 14Acticor Biotech Announces Chief Financial Officer ChangesActicor Biotech announced the appointment of François Guillet as Chief Financial Officer, replacing Éric Cohen who is leaving to pursue other projects. With over 30 years' experience in financial management, François Guillet will bring to Acticor Biotech his expertise in financial structuring and optimization. His role will be to strengthen the management of the company's finances, while ensuring long-term visibility of Acticor Biotech's global strategy. François Guillet has held positions of great responsibility in companies in a wide variety of sectors, including the high-tech sector, from software publishing at Bea, Oracle and Adobe to the internet, electronics and e-commerce at Monnier Frères. He has contributed to restructuring and turnaround projects in mid-sized companies, with scope extended to Human Resources, Purchasing and Sales Administration. His previous assignments have included managing accounting closures, due diligence and managing multicultural teams internationally, reinforcing his versatility as a financial leader.お知らせ • Oct 11Acticor Biotech Repositions Glenzocimab in the Treatment of Myocardial InfarctionACTICOR BIOTECH provided an update on its clinical developments evaluating glenzocimab in the treatment of myocardial infarction. LIBERATE: A phase 2b study evaluating glenzocimab in the treatment of myocardial infarction. The LIBERATE phase 2b, randomized and double-blind study will include more than 212 patients suffering from ST-Elevation Myocardial Infarction (STEMI) who are scheduled to undergo percutaneous coronary intervention (PCI). The study’s primary objective is to assess the safety and efficacy of glenzocimab 1,000 mg compared to placebo, in reducing the size of the myocardial infarction 90 days post-event. This study is being conducted in partnership with the University of Birmingham (UK), with clinical experts from the Institute of Cardiovascular Sciences and University Hospitals Birmingham NHS Foundation Trust. The two leading clinical research sites, Queen Elizabeth Hospital in Birmingham and Northern General Hospitalin Sheffield, have been actively recruiting patients since January 2024. To date, 27 patients have been recruited, and study results are expected in Fourth Quarter of 2026. GLORIA: A phase 2 study evaluating glenzocimab in myocardial infarction treatment. A new phase 2 study GLORIA, randomized and double-blind, is being prepared to evaluate glenzocimab in the treatment of myocardial infarction. The study will enroll around 300 patients suffering from STEMI upon emergency admission to cardiac intensive care units. The study’s primary objective is likewise to assess the efficacy of glenzocimab for reducing the surface of myocardial infarct at Day 90 post PCI (Percutaneous Coronary Intervention), as well as safety. The study plans to test several dose levels and optimize the mode of administration to suit the time required for this emergency procedure. The aim of launching this second study, which could be promoted by the Company, is to provide all the clinical and regulatory elements required for a phase 3 registration as early as 2027, while evolving the product's mode of administration to facilitate the next stage of development and, later, adoption by clinicians. Patient recruitment could begin in First Quarter 2025, subject to the Company's financing or the continuation of the project as envisaged in the receivership procedure.Board Change • Sep 17Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Patricia Zilliox was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 14Acticor Biotech SAS, Annual General Meeting, Oct 25, 2024Acticor Biotech SAS, Annual General Meeting, Oct 25, 2024. Location: 82 avenue du maine, paris Franceお知らせ • Jul 26Acticor Biotech Announces the Conclusions of the Interim Futility Analysis in the Green StudyActicor Biotech announced the conclusions of the futility analysis of the phase 2/3 GREEN study evaluating glenzocimab as an adjunct to mechanical thrombectomy in acute ischemic stroke. In the light of the information provided to the members of the Independent Monitoring Committee (IMC), and in accordance with the futility criteria defined in the protocol, the IMC recommends that the GREEN study be discontinued. In light of the Committee's recommendations, sponsor Assistance Publique Hôpitaux de Paris (APHP), in agreement with Professor Mikaël Mazighi, principal investigator of the study, has decided to stop the GREEN study and halt enrolment. To date, 108 patients have been included in the study, the futility analysis only covered the first 78 patients, and all included patients will be analysed after the 90-day protocol follow-up. The GREEN study, sponsored by Assistance Publique - Hôpitaux de Paris, is part of the RHU BOOSTER program, with financial support from the Agence Nationale de la Recherche and the Programme Investissements d'Avenir. GREEN (Glenzocimab for REperfusion in the setting of Endovascular therapy for brain infarctioN) is a randomized, double-blind, multicenter, placebo-controlled Phase 2/3 study of the efficacy and safety of glenzocimab as an adjunct to mechanical thrombectomy in the first 24 hours of acute ischemic stroke.New Risk • Jul 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.80m (US$9.53m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€8.80m market cap, or US$9.53m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (28% increase in shares outstanding).Board Change • May 17Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Patricia Zilliox was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.お知らせ • May 16Acticor Biotech Announces Presentation of the Main Results of the Phase 2/3 Actisave Study in the Treatment of Stroke at ESOC 2024Acticor Biotech SAS announced the presentation on May 15, 2024 during the opening session of the 10thEuropean Stroke Organisation Conference (ESOC), of the phase 2/3 study results, ACTISAVE, in the treatment of acute ischemic stroke. During this conference, in the "Hyperacute Management" session on May 15, Dr. Davide Carone from Brainomix Ltd. will also present the latest brain imaging analyses obtained in the ACTIMIS study: "Patients randomized to Glenzocimab suffered less hemorrhagic transformation with greater benefit in larger baseline infarct core," reinforcing the potential of glenzocimab in certain patient subpopulations, particularly those presenting larger volumes of cerebral infarction at baseline. Glenzocimab is also being evaluated in two other clinical studies conducted by academic teams, which do not question their work and confirm their confidence in the potential of the product. Phase 2/3 GREEN study in the treatment of stroke in patients undergoing mechanical thrombectomy with a futility analysis after the inclusion of the first 78 patients (30% of patients) expected in the fourth quarter of 2024; Phase 2b LIBERATE study in the treatment of myocardial infarction with final results expected in the fourth quarter of 2025. The company plans to actively continue discussions with pharmaceutical partners to explore potential strategic collaborations that could support future phases of glenzocimab's development and clinical application. As announced on April 25, 2024, during the release of the ACTISAVE results, the company is able to fund its operations until October 2024. The European Stroke Organisation (ESO) is a pan-European society of researchers and physicians specializing in strokes, national and regional stroke societies, and non-professional organizations, founded in December 2007. ESO is a non-governmental organization composed of individual and organizational members. ESO serves as the voice of stroke in Europe, harmonizing stroke care across Europe and taking action to reduce the burden of stroke at regional and global levels.お知らせ • Apr 26Acticor Biotech SAS Announces Topline Results of ACTISAVE Phase 2/3 Study in Stroke TreatmentActicor Biotech SAS announced the first results of its ACTISAVE phase 2/3 study in the treatment of acute ischemic stroke. Analysis of the first results shows no evidence of efficacy for either the primary endpoint, the proportion of patients with severe disability or death (mRS 4-6) at 90 days after the stroke, or for the secondary endpoint, the proportion of patients with no disability (mRS 0-2) at 90 days. As a reminder, ACTISAVE (NCT05070260), an international, adaptive, multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2/3 study, evaluated the safety and efficacy of a single dose of glenzocimab used in combination with the standard of care (thrombolysis +/- thrombectomy) for acute ischemic stroke. The study was deployed in the United States, Europe (8 countries), Israel and the United Kingdom. Glenzocimab is currently evaluated in two other clinical studies sponsored by academic teams: A Phase 2/3 GREEN study in stroke patients undergoing mechanical thrombectomy, with a futility analysis following the inclusion of the first 78 patients (30% of patients) expected in Fourth Quarter 2024. A phase 2b LIBERATE study in the treatment of myocardial infarction, with final results expected in Fourth Quarter 2025.お知らせ • Apr 15Acticor Biotech Will Present the Clinical Results of Its Phase 2/3 Actisave Study in the Treatment of Stroke At Esoc 2024Acticor Biotech SAS announces its participation in the European Stroke Organization Conference (ESOC) 2024, to be held from 15 to 17 May 2024 in Basel, Switzerland. ESOC is the leading European forum for stroke research and the preferred platform for the publication of major clinical trial data. As a reminder, ACTISAVE (NCT05070260) is an international, adaptive, multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2/3 study evaluating the safety and efficacy of a single dose of glenzocimab used in combination with the standard of care (thrombolysis +/- thrombectomy) for acute ischemic stroke. Deployed in the United States, Europe, Israel, and United Kingdom, ACTISAVE has enrolled 438 patients, of whom about 40% have undergone mechanical thrombectomy.Board Change • Mar 18Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Patricia Zilliox was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.お知らせ • Mar 16Acticor Biotech SAS has completed a Follow-on Equity Offering in the amount of €8.031849 million.Acticor Biotech SAS has completed a Follow-on Equity Offering in the amount of €8.031849 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,261,260 Price\Range: €3.13 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 304,826 Price\Range: €3.13 Transaction Features: Reserved Share Offeringお知らせ • Mar 15Acticor Biotech SAS has filed a Follow-on Equity Offering in the amount of €7 million.Acticor Biotech SAS has filed a Follow-on Equity Offering in the amount of €7 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,236,422 Price\Range: €3.13 Transaction Features: Reserved Share Offeringお知らせ • Feb 08The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart AttackThe University of Birmingham and Acticor Biotech announced the first patient treated in the LIBERATE clinical study to evaluate glenzocimab efficacy in myocardial infarction. In 2022, the University of Birmingham and Actic or Biotech signed a partnership agreement to evaluate glenzocim AB efficacy in myocardial infARction in a new clinical trial called LIBERATE. Having obtained full regulatory approval in August 2023, two cutting-edge clinical research sites, namely the Queen Elizabeth Hospital in Birmingham and the Northern General Hospital in Sheffield, are involved in the study. The primary objective of the study is to evaluate both the safety and efficacy of glenzocimab at a dosage of 1000 mg compared to a placebo, specifically focusing on the reduction of myocardial infarct size at Day 90 post-treatment. Dr. Mark Thomas, Associate Professor of Cardiology at the University of Birmingham and Honorary Consultant Cardiologist and Director of the Cardiovascular Research Unit at Northern General Hospital, said: "We are very happy to have started recruit into the LIBERATE clinical trial. This is the first time worldwide that this class of medication has been investigated in patients with heart attacks, after showing great promise in patients with stroke. The company are very pleased to now recruit patients in the LIBERATE clinical trial".お知らせ • Jan 26Acticor Biotech SAS to Report Fiscal Year 2023 Results on Apr 30, 2024Acticor Biotech SAS announced that they will report fiscal year 2023 results on Apr 30, 2024お知らせ • Jan 23Acticor Biotech Announces Publication of ACTIMIS Clinical Study Results in the Lancet Neurology JournalACTICOR BIOTECH announced the publication of phase 1b/2a clinical results of ACTIMIS study in The Lancet Neurology Journal. The manuscript is entitled: Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a phase 1b/2a randomized, placebo-controlled, trial. The ACTIMIS clinical trial evaluated glenzocimab in combination with the reference treatment (thrombolysis with or without thrombectomy) in patients presenting with an Acute Ischemic Stroke. This publication displays the full analysis of ACTIMIS results. The key results presented in the manuscript are: Achievement of ACTIMIS primary endpoint, confirming the safety of glenzocimab in AIS patients; In phase 2a, glenzocimab 1000 mg, as add-on therapy to alteplase, was associated with reduced symptomatic intracerebral haemorrhage (0% vs 10%) and all-cause mortality (8% vs 21%) compared with placebo; Patients with the most severe strokes and at highest risk of intracranial haemorrhage might be the best responders in this study. The results of ACTIMIS were first presented during the European Stroke Organisation Conference (ESOC) in 2022. Find here previous exchanges with Professor Mikael Mazighi MD, PhD who is the global study coordinator: The media presentation: As a reminder, the ongoing phase 2/3 clinical trial ACTISAVE has completed its recruitment in October 2023 with expected results in the second quarter of 2024.お知らせ • Nov 29Acticor Biotech SAS has filed a Follow-on Equity Offering in the amount of €2.55108 million.Acticor Biotech SAS has filed a Follow-on Equity Offering in the amount of €2.55108 million. Security Name: Shares Security Type: Common Stock Securities Offered: 850,360 Price\Range: €3Breakeven Date Change • Nov 29Forecast to breakeven in 2025The analyst covering Acticor Biotech SAS expects the company to break even for the first time. New forecast suggests the company will make a profit of €16.4m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.お知らせ • Nov 10ACTICOR BIOTECH Announces Timely Completed Patient Recruitment of Its Phase 2/3 Study in StrokeACTICOR BIOTECH announced the timely completion of enrollment in the ACTISAVE Phase 2/3 clinical trial in patients with acute ischemic stroke (AIS). ACTISAVE (NCT05070260) is an international, adaptive, multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2/3 study evaluating the safety and efficacy of a single dose of glenzocimab used in combination with the standard of care (thrombolysis +/- thrombectomy) for acute ischemic stroke. Deployed in the United States, Europe, Israel, and United Kingdom, ACTISAVE has enrolled 438 patients, of whom about 40% have undergone mechanical thrombectomy. As a reminder, following consultations with the European (EMA) and American (FDA) regulatory agencies, and in agreement with ACTISAVE Scientific Committee, Acticor Biotech decided in September 2023 to change the main endpoint of the study by retaining only one single endpoint, namely the reduction in the number of patients whoied or suffered from severe disability as a result of AIS (mRS score 4-6 at 90 days). As previously announced, phase 2/3 clinical results are expected in the second quarter of 2024. Based on these results and the recommendations of international experts in stroke, Acticor Biotech plans to consult again with the EMA and the FDA in 2024 to confirm that the Phase 3 design will support final registration in both Europe and the United States, envisaged by 2028 at the latest.New Risk • Oct 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€2.2m). Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€21m net loss in 3 years). Share price has been volatile over the past 3 months (6.3% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€52.9m market cap, or US$56.0m).お知らせ • Sep 08Acticor Biotech and University of Birmingham Announces The UK Regulatory Agency (MHRA) Approves the Protocol of LIBERATE Study, the First Clinical Trial Evaluating Glenzocimab for Heart AttacksOn September 7th, 2023, the University of Birmingham and Acticor Biotech announced the full regulatory approval of LIBERATE clinical study. In 2021, the University of Birmingham and Acticor Biotech signed a partnership agreement to evaluate glenzocimab efficacy in myocardial infarction in a new clinical trial called LIBERATE. The University has received full regulatory approvals to initiate the study. This new clinical trial is based on a long-standing collaboration between Acticor Biotech and the University of Birmingham. The publication in August of a scientific paper from Dr Mark Thomas entitled: “Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy “ (link to the publication) in the Journal of Thrombosis and Haemostasis, reinforced the mode of action of glenzocimab and its major role as an antithrombotic drug. The randomised, double-blind Phase 2b LIBERATE study will recruit more than 200 patients suffering from a ST-elevation myocardial infarction (STEMI) and planned for a percutaneous coronary intervention. The study aims to assess the safety and the efficacy of glenzocimab 1000 mg versus placebo to reduce the myocardial infarct size at Day 90 post-treatment. The trial will be conducted in two acute care hospitals in the UK: the Queen Elizabeth Hospital, Birmingham and the Northern General Hospital, Sheffield. Patient recruitment is expected to start by the end of 2023.Breakeven Date Change • Jul 26Forecast to breakeven in 2023The analyst covering Acticor Biotech SAS expects the company to break even for the first time. New forecast suggests the company will make a profit of €924.9k in 2023.Board Change • Jul 26Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Patricia Zilliox was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.株主還元7V7DE BiotechsDE 市場7D0%2.9%-0.2%1Y-74.3%-5.6%1.3%株主還元を見る業界別リターン: 7V7過去 1 年間で-5.6 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: 7V7は、過去 1 年間で1.3 % のリターンを上げたGerman市場を下回りました。価格変動Is 7V7's price volatile compared to industry and market?7V7 volatility7V7 Average Weekly Movementn/aBiotechs Industry Average Movement8.3%Market Average Movement5.6%10% most volatile stocks in DE Market13.3%10% least volatile stocks in DE Market2.8%安定した株価: 7V7の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間の7V7のボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト201331Gilles Avenardwww.acticor-biotech.comActicor Biotech SAS社は、急性血栓性疾患の治療薬を開発する臨床段階のバイオ製薬会社である。同社は、血小板糖タンパク質VIを標的とするヒト化モノクローナル抗体フラグメントであるグレンゾシマブを開発している。同社の製品であるglenzocimabは、急性虚血性脳卒中治療薬としてフェーズ1b/2aを完了し、急性呼吸窮迫症候群（covid-19）治療薬としてフェーズ2/3を完了し、急性虚血性脳卒中治療薬としてフェーズ1b/2aを完了し、急性呼吸窮迫症候群（covid-19）治療薬としてフェーズ2/3を完了し、急性呼吸窮迫症候群（covid-19）治療薬としてフェーズ2/3を完了した。バーミンガム大学とは、心臓発作を対象としたグレンゾシマブの第2b相臨床試験に関する共同研究契約を締結している。同社は2013年に設立され、フランスのパリに本社を置いている。もっと見るActicor Biotech SAS 基礎のまとめActicor Biotech SAS の収益と売上を時価総額と比較するとどうか。7V7 基礎統計学時価総額€3.92m収益（TTM）-€16.47m売上高(TTM)n/a0.0xP/Sレシオ-0.2xPER（株価収益率7V7 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計7V7 損益計算書（TTM）収益€0売上原価€0売上総利益€0その他の費用€16.47m収益-€16.47m直近の収益報告Jun 30, 2024次回決算日該当なし一株当たり利益（EPS）-1.05グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-137.0%7V7 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/01/12 13:40終値2024/10/15 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Acticor Biotech SAS 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Guillaume CuvillierGilbert DupontStephanie LefebvreGilbert Dupont
お知らせ • Mar 07Acticor Biotech SAS(ENXTPA:ALACT) dropped from Next Biotech IndexActicor Biotech SAS has been dropped from the Next Biotech Index.
お知らせ • Oct 14Acticor Biotech Announces Chief Financial Officer ChangesActicor Biotech announced the appointment of François Guillet as Chief Financial Officer, replacing Éric Cohen who is leaving to pursue other projects. With over 30 years' experience in financial management, François Guillet will bring to Acticor Biotech his expertise in financial structuring and optimization. His role will be to strengthen the management of the company's finances, while ensuring long-term visibility of Acticor Biotech's global strategy. François Guillet has held positions of great responsibility in companies in a wide variety of sectors, including the high-tech sector, from software publishing at Bea, Oracle and Adobe to the internet, electronics and e-commerce at Monnier Frères. He has contributed to restructuring and turnaround projects in mid-sized companies, with scope extended to Human Resources, Purchasing and Sales Administration. His previous assignments have included managing accounting closures, due diligence and managing multicultural teams internationally, reinforcing his versatility as a financial leader.
お知らせ • Oct 11Acticor Biotech Repositions Glenzocimab in the Treatment of Myocardial InfarctionACTICOR BIOTECH provided an update on its clinical developments evaluating glenzocimab in the treatment of myocardial infarction. LIBERATE: A phase 2b study evaluating glenzocimab in the treatment of myocardial infarction. The LIBERATE phase 2b, randomized and double-blind study will include more than 212 patients suffering from ST-Elevation Myocardial Infarction (STEMI) who are scheduled to undergo percutaneous coronary intervention (PCI). The study’s primary objective is to assess the safety and efficacy of glenzocimab 1,000 mg compared to placebo, in reducing the size of the myocardial infarction 90 days post-event. This study is being conducted in partnership with the University of Birmingham (UK), with clinical experts from the Institute of Cardiovascular Sciences and University Hospitals Birmingham NHS Foundation Trust. The two leading clinical research sites, Queen Elizabeth Hospital in Birmingham and Northern General Hospitalin Sheffield, have been actively recruiting patients since January 2024. To date, 27 patients have been recruited, and study results are expected in Fourth Quarter of 2026. GLORIA: A phase 2 study evaluating glenzocimab in myocardial infarction treatment. A new phase 2 study GLORIA, randomized and double-blind, is being prepared to evaluate glenzocimab in the treatment of myocardial infarction. The study will enroll around 300 patients suffering from STEMI upon emergency admission to cardiac intensive care units. The study’s primary objective is likewise to assess the efficacy of glenzocimab for reducing the surface of myocardial infarct at Day 90 post PCI (Percutaneous Coronary Intervention), as well as safety. The study plans to test several dose levels and optimize the mode of administration to suit the time required for this emergency procedure. The aim of launching this second study, which could be promoted by the Company, is to provide all the clinical and regulatory elements required for a phase 3 registration as early as 2027, while evolving the product's mode of administration to facilitate the next stage of development and, later, adoption by clinicians. Patient recruitment could begin in First Quarter 2025, subject to the Company's financing or the continuation of the project as envisaged in the receivership procedure.
Board Change • Sep 17Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Patricia Zilliox was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 14Acticor Biotech SAS, Annual General Meeting, Oct 25, 2024Acticor Biotech SAS, Annual General Meeting, Oct 25, 2024. Location: 82 avenue du maine, paris France
お知らせ • Jul 26Acticor Biotech Announces the Conclusions of the Interim Futility Analysis in the Green StudyActicor Biotech announced the conclusions of the futility analysis of the phase 2/3 GREEN study evaluating glenzocimab as an adjunct to mechanical thrombectomy in acute ischemic stroke. In the light of the information provided to the members of the Independent Monitoring Committee (IMC), and in accordance with the futility criteria defined in the protocol, the IMC recommends that the GREEN study be discontinued. In light of the Committee's recommendations, sponsor Assistance Publique Hôpitaux de Paris (APHP), in agreement with Professor Mikaël Mazighi, principal investigator of the study, has decided to stop the GREEN study and halt enrolment. To date, 108 patients have been included in the study, the futility analysis only covered the first 78 patients, and all included patients will be analysed after the 90-day protocol follow-up. The GREEN study, sponsored by Assistance Publique - Hôpitaux de Paris, is part of the RHU BOOSTER program, with financial support from the Agence Nationale de la Recherche and the Programme Investissements d'Avenir. GREEN (Glenzocimab for REperfusion in the setting of Endovascular therapy for brain infarctioN) is a randomized, double-blind, multicenter, placebo-controlled Phase 2/3 study of the efficacy and safety of glenzocimab as an adjunct to mechanical thrombectomy in the first 24 hours of acute ischemic stroke.
お知らせ • Mar 07Acticor Biotech SAS(ENXTPA:ALACT) dropped from Next Biotech IndexActicor Biotech SAS has been dropped from the Next Biotech Index.
お知らせ • Oct 14Acticor Biotech Announces Chief Financial Officer ChangesActicor Biotech announced the appointment of François Guillet as Chief Financial Officer, replacing Éric Cohen who is leaving to pursue other projects. With over 30 years' experience in financial management, François Guillet will bring to Acticor Biotech his expertise in financial structuring and optimization. His role will be to strengthen the management of the company's finances, while ensuring long-term visibility of Acticor Biotech's global strategy. François Guillet has held positions of great responsibility in companies in a wide variety of sectors, including the high-tech sector, from software publishing at Bea, Oracle and Adobe to the internet, electronics and e-commerce at Monnier Frères. He has contributed to restructuring and turnaround projects in mid-sized companies, with scope extended to Human Resources, Purchasing and Sales Administration. His previous assignments have included managing accounting closures, due diligence and managing multicultural teams internationally, reinforcing his versatility as a financial leader.
お知らせ • Oct 11Acticor Biotech Repositions Glenzocimab in the Treatment of Myocardial InfarctionACTICOR BIOTECH provided an update on its clinical developments evaluating glenzocimab in the treatment of myocardial infarction. LIBERATE: A phase 2b study evaluating glenzocimab in the treatment of myocardial infarction. The LIBERATE phase 2b, randomized and double-blind study will include more than 212 patients suffering from ST-Elevation Myocardial Infarction (STEMI) who are scheduled to undergo percutaneous coronary intervention (PCI). The study’s primary objective is to assess the safety and efficacy of glenzocimab 1,000 mg compared to placebo, in reducing the size of the myocardial infarction 90 days post-event. This study is being conducted in partnership with the University of Birmingham (UK), with clinical experts from the Institute of Cardiovascular Sciences and University Hospitals Birmingham NHS Foundation Trust. The two leading clinical research sites, Queen Elizabeth Hospital in Birmingham and Northern General Hospitalin Sheffield, have been actively recruiting patients since January 2024. To date, 27 patients have been recruited, and study results are expected in Fourth Quarter of 2026. GLORIA: A phase 2 study evaluating glenzocimab in myocardial infarction treatment. A new phase 2 study GLORIA, randomized and double-blind, is being prepared to evaluate glenzocimab in the treatment of myocardial infarction. The study will enroll around 300 patients suffering from STEMI upon emergency admission to cardiac intensive care units. The study’s primary objective is likewise to assess the efficacy of glenzocimab for reducing the surface of myocardial infarct at Day 90 post PCI (Percutaneous Coronary Intervention), as well as safety. The study plans to test several dose levels and optimize the mode of administration to suit the time required for this emergency procedure. The aim of launching this second study, which could be promoted by the Company, is to provide all the clinical and regulatory elements required for a phase 3 registration as early as 2027, while evolving the product's mode of administration to facilitate the next stage of development and, later, adoption by clinicians. Patient recruitment could begin in First Quarter 2025, subject to the Company's financing or the continuation of the project as envisaged in the receivership procedure.
Board Change • Sep 17Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Patricia Zilliox was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 14Acticor Biotech SAS, Annual General Meeting, Oct 25, 2024Acticor Biotech SAS, Annual General Meeting, Oct 25, 2024. Location: 82 avenue du maine, paris France
お知らせ • Jul 26Acticor Biotech Announces the Conclusions of the Interim Futility Analysis in the Green StudyActicor Biotech announced the conclusions of the futility analysis of the phase 2/3 GREEN study evaluating glenzocimab as an adjunct to mechanical thrombectomy in acute ischemic stroke. In the light of the information provided to the members of the Independent Monitoring Committee (IMC), and in accordance with the futility criteria defined in the protocol, the IMC recommends that the GREEN study be discontinued. In light of the Committee's recommendations, sponsor Assistance Publique Hôpitaux de Paris (APHP), in agreement with Professor Mikaël Mazighi, principal investigator of the study, has decided to stop the GREEN study and halt enrolment. To date, 108 patients have been included in the study, the futility analysis only covered the first 78 patients, and all included patients will be analysed after the 90-day protocol follow-up. The GREEN study, sponsored by Assistance Publique - Hôpitaux de Paris, is part of the RHU BOOSTER program, with financial support from the Agence Nationale de la Recherche and the Programme Investissements d'Avenir. GREEN (Glenzocimab for REperfusion in the setting of Endovascular therapy for brain infarctioN) is a randomized, double-blind, multicenter, placebo-controlled Phase 2/3 study of the efficacy and safety of glenzocimab as an adjunct to mechanical thrombectomy in the first 24 hours of acute ischemic stroke.
New Risk • Jul 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.80m (US$9.53m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€8.80m market cap, or US$9.53m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (28% increase in shares outstanding).
Board Change • May 17Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Patricia Zilliox was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
お知らせ • May 16Acticor Biotech Announces Presentation of the Main Results of the Phase 2/3 Actisave Study in the Treatment of Stroke at ESOC 2024Acticor Biotech SAS announced the presentation on May 15, 2024 during the opening session of the 10thEuropean Stroke Organisation Conference (ESOC), of the phase 2/3 study results, ACTISAVE, in the treatment of acute ischemic stroke. During this conference, in the "Hyperacute Management" session on May 15, Dr. Davide Carone from Brainomix Ltd. will also present the latest brain imaging analyses obtained in the ACTIMIS study: "Patients randomized to Glenzocimab suffered less hemorrhagic transformation with greater benefit in larger baseline infarct core," reinforcing the potential of glenzocimab in certain patient subpopulations, particularly those presenting larger volumes of cerebral infarction at baseline. Glenzocimab is also being evaluated in two other clinical studies conducted by academic teams, which do not question their work and confirm their confidence in the potential of the product. Phase 2/3 GREEN study in the treatment of stroke in patients undergoing mechanical thrombectomy with a futility analysis after the inclusion of the first 78 patients (30% of patients) expected in the fourth quarter of 2024; Phase 2b LIBERATE study in the treatment of myocardial infarction with final results expected in the fourth quarter of 2025. The company plans to actively continue discussions with pharmaceutical partners to explore potential strategic collaborations that could support future phases of glenzocimab's development and clinical application. As announced on April 25, 2024, during the release of the ACTISAVE results, the company is able to fund its operations until October 2024. The European Stroke Organisation (ESO) is a pan-European society of researchers and physicians specializing in strokes, national and regional stroke societies, and non-professional organizations, founded in December 2007. ESO is a non-governmental organization composed of individual and organizational members. ESO serves as the voice of stroke in Europe, harmonizing stroke care across Europe and taking action to reduce the burden of stroke at regional and global levels.
お知らせ • Apr 26Acticor Biotech SAS Announces Topline Results of ACTISAVE Phase 2/3 Study in Stroke TreatmentActicor Biotech SAS announced the first results of its ACTISAVE phase 2/3 study in the treatment of acute ischemic stroke. Analysis of the first results shows no evidence of efficacy for either the primary endpoint, the proportion of patients with severe disability or death (mRS 4-6) at 90 days after the stroke, or for the secondary endpoint, the proportion of patients with no disability (mRS 0-2) at 90 days. As a reminder, ACTISAVE (NCT05070260), an international, adaptive, multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2/3 study, evaluated the safety and efficacy of a single dose of glenzocimab used in combination with the standard of care (thrombolysis +/- thrombectomy) for acute ischemic stroke. The study was deployed in the United States, Europe (8 countries), Israel and the United Kingdom. Glenzocimab is currently evaluated in two other clinical studies sponsored by academic teams: A Phase 2/3 GREEN study in stroke patients undergoing mechanical thrombectomy, with a futility analysis following the inclusion of the first 78 patients (30% of patients) expected in Fourth Quarter 2024. A phase 2b LIBERATE study in the treatment of myocardial infarction, with final results expected in Fourth Quarter 2025.
お知らせ • Apr 15Acticor Biotech Will Present the Clinical Results of Its Phase 2/3 Actisave Study in the Treatment of Stroke At Esoc 2024Acticor Biotech SAS announces its participation in the European Stroke Organization Conference (ESOC) 2024, to be held from 15 to 17 May 2024 in Basel, Switzerland. ESOC is the leading European forum for stroke research and the preferred platform for the publication of major clinical trial data. As a reminder, ACTISAVE (NCT05070260) is an international, adaptive, multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2/3 study evaluating the safety and efficacy of a single dose of glenzocimab used in combination with the standard of care (thrombolysis +/- thrombectomy) for acute ischemic stroke. Deployed in the United States, Europe, Israel, and United Kingdom, ACTISAVE has enrolled 438 patients, of whom about 40% have undergone mechanical thrombectomy.
Board Change • Mar 18Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Patricia Zilliox was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
お知らせ • Mar 16Acticor Biotech SAS has completed a Follow-on Equity Offering in the amount of €8.031849 million.Acticor Biotech SAS has completed a Follow-on Equity Offering in the amount of €8.031849 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,261,260 Price\Range: €3.13 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 304,826 Price\Range: €3.13 Transaction Features: Reserved Share Offering
お知らせ • Mar 15Acticor Biotech SAS has filed a Follow-on Equity Offering in the amount of €7 million.Acticor Biotech SAS has filed a Follow-on Equity Offering in the amount of €7 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,236,422 Price\Range: €3.13 Transaction Features: Reserved Share Offering
お知らせ • Feb 08The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart AttackThe University of Birmingham and Acticor Biotech announced the first patient treated in the LIBERATE clinical study to evaluate glenzocimab efficacy in myocardial infarction. In 2022, the University of Birmingham and Actic or Biotech signed a partnership agreement to evaluate glenzocim AB efficacy in myocardial infARction in a new clinical trial called LIBERATE. Having obtained full regulatory approval in August 2023, two cutting-edge clinical research sites, namely the Queen Elizabeth Hospital in Birmingham and the Northern General Hospital in Sheffield, are involved in the study. The primary objective of the study is to evaluate both the safety and efficacy of glenzocimab at a dosage of 1000 mg compared to a placebo, specifically focusing on the reduction of myocardial infarct size at Day 90 post-treatment. Dr. Mark Thomas, Associate Professor of Cardiology at the University of Birmingham and Honorary Consultant Cardiologist and Director of the Cardiovascular Research Unit at Northern General Hospital, said: "We are very happy to have started recruit into the LIBERATE clinical trial. This is the first time worldwide that this class of medication has been investigated in patients with heart attacks, after showing great promise in patients with stroke. The company are very pleased to now recruit patients in the LIBERATE clinical trial".
お知らせ • Jan 26Acticor Biotech SAS to Report Fiscal Year 2023 Results on Apr 30, 2024Acticor Biotech SAS announced that they will report fiscal year 2023 results on Apr 30, 2024
お知らせ • Jan 23Acticor Biotech Announces Publication of ACTIMIS Clinical Study Results in the Lancet Neurology JournalACTICOR BIOTECH announced the publication of phase 1b/2a clinical results of ACTIMIS study in The Lancet Neurology Journal. The manuscript is entitled: Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a phase 1b/2a randomized, placebo-controlled, trial. The ACTIMIS clinical trial evaluated glenzocimab in combination with the reference treatment (thrombolysis with or without thrombectomy) in patients presenting with an Acute Ischemic Stroke. This publication displays the full analysis of ACTIMIS results. The key results presented in the manuscript are: Achievement of ACTIMIS primary endpoint, confirming the safety of glenzocimab in AIS patients; In phase 2a, glenzocimab 1000 mg, as add-on therapy to alteplase, was associated with reduced symptomatic intracerebral haemorrhage (0% vs 10%) and all-cause mortality (8% vs 21%) compared with placebo; Patients with the most severe strokes and at highest risk of intracranial haemorrhage might be the best responders in this study. The results of ACTIMIS were first presented during the European Stroke Organisation Conference (ESOC) in 2022. Find here previous exchanges with Professor Mikael Mazighi MD, PhD who is the global study coordinator: The media presentation: As a reminder, the ongoing phase 2/3 clinical trial ACTISAVE has completed its recruitment in October 2023 with expected results in the second quarter of 2024.
お知らせ • Nov 29Acticor Biotech SAS has filed a Follow-on Equity Offering in the amount of €2.55108 million.Acticor Biotech SAS has filed a Follow-on Equity Offering in the amount of €2.55108 million. Security Name: Shares Security Type: Common Stock Securities Offered: 850,360 Price\Range: €3
Breakeven Date Change • Nov 29Forecast to breakeven in 2025The analyst covering Acticor Biotech SAS expects the company to break even for the first time. New forecast suggests the company will make a profit of €16.4m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.
お知らせ • Nov 10ACTICOR BIOTECH Announces Timely Completed Patient Recruitment of Its Phase 2/3 Study in StrokeACTICOR BIOTECH announced the timely completion of enrollment in the ACTISAVE Phase 2/3 clinical trial in patients with acute ischemic stroke (AIS). ACTISAVE (NCT05070260) is an international, adaptive, multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2/3 study evaluating the safety and efficacy of a single dose of glenzocimab used in combination with the standard of care (thrombolysis +/- thrombectomy) for acute ischemic stroke. Deployed in the United States, Europe, Israel, and United Kingdom, ACTISAVE has enrolled 438 patients, of whom about 40% have undergone mechanical thrombectomy. As a reminder, following consultations with the European (EMA) and American (FDA) regulatory agencies, and in agreement with ACTISAVE Scientific Committee, Acticor Biotech decided in September 2023 to change the main endpoint of the study by retaining only one single endpoint, namely the reduction in the number of patients whoied or suffered from severe disability as a result of AIS (mRS score 4-6 at 90 days). As previously announced, phase 2/3 clinical results are expected in the second quarter of 2024. Based on these results and the recommendations of international experts in stroke, Acticor Biotech plans to consult again with the EMA and the FDA in 2024 to confirm that the Phase 3 design will support final registration in both Europe and the United States, envisaged by 2028 at the latest.
New Risk • Oct 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€2.2m). Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€21m net loss in 3 years). Share price has been volatile over the past 3 months (6.3% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€52.9m market cap, or US$56.0m).
お知らせ • Sep 08Acticor Biotech and University of Birmingham Announces The UK Regulatory Agency (MHRA) Approves the Protocol of LIBERATE Study, the First Clinical Trial Evaluating Glenzocimab for Heart AttacksOn September 7th, 2023, the University of Birmingham and Acticor Biotech announced the full regulatory approval of LIBERATE clinical study. In 2021, the University of Birmingham and Acticor Biotech signed a partnership agreement to evaluate glenzocimab efficacy in myocardial infarction in a new clinical trial called LIBERATE. The University has received full regulatory approvals to initiate the study. This new clinical trial is based on a long-standing collaboration between Acticor Biotech and the University of Birmingham. The publication in August of a scientific paper from Dr Mark Thomas entitled: “Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy “ (link to the publication) in the Journal of Thrombosis and Haemostasis, reinforced the mode of action of glenzocimab and its major role as an antithrombotic drug. The randomised, double-blind Phase 2b LIBERATE study will recruit more than 200 patients suffering from a ST-elevation myocardial infarction (STEMI) and planned for a percutaneous coronary intervention. The study aims to assess the safety and the efficacy of glenzocimab 1000 mg versus placebo to reduce the myocardial infarct size at Day 90 post-treatment. The trial will be conducted in two acute care hospitals in the UK: the Queen Elizabeth Hospital, Birmingham and the Northern General Hospital, Sheffield. Patient recruitment is expected to start by the end of 2023.
Breakeven Date Change • Jul 26Forecast to breakeven in 2023The analyst covering Acticor Biotech SAS expects the company to break even for the first time. New forecast suggests the company will make a profit of €924.9k in 2023.
Board Change • Jul 26Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Patricia Zilliox was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
